Organovo Holdings (NASDAQ: ONVO)
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-07 | ||||||
REV |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-19 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Organovo Holdings (NASDAQ: ONVO) through any online brokerage.
Other companies in Organovo Holdings’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Brooklyn (NASDAQ:BTX), Monopar Therapeutics (NASDAQ:MNPR) and Larimar Therapeutics (NASDAQ:LRMR).
The latest price target for Organovo Holdings (NASDAQ: ONVO) was reported by HC Wainwright & Co. on Thursday, August 8, 2019. The analyst firm set a price target for 0.00 expecting ONVO to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
The stock price for Organovo Holdings (NASDAQ: ONVO) is $3.21 last updated August 5, 2022, 8:00 PM UTC.
There are no upcoming dividends for Organovo Holdings.
Organovo Holdings’s Q2 earnings are confirmed for Monday, November 7, 2022.
There is no upcoming split for Organovo Holdings.
Organovo Holdings is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.